Peripheral oedema
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Peripheral oedema
Laboratory tests
- NT-proBNP
- Serum albumin
- Total serum protein
- PT ± factor V
- AST
- ALT
- GGT
- ALP
- Serum creatinine with eGFR
- FBC (if the cause remains unexplained)if needednon-French guidelineBilateral oedema whose cause remains unexplained after clinical examination: short additional list to rule out a systemic cause [2].
- Serum electrolytes (if the cause remains unexplained)if needednon-French guidelineBilateral oedema whose cause remains unexplained after clinical examination: short additional list to rule out a systemic cause [2].
- TSH (if the cause remains unexplained)if needednon-French guidelineBilateral oedema whose cause remains unexplained after clinical examination: short additional list to rule out a systemic cause [2]. Myxoedema is among the causes of chronic bilateral oedema [2].
- Fasting plasma glucose (if the cause remains unexplained)if needednon-French guidelineUnexplained bilateral oedema: the American review already cited includes plasma glucose in its short list [2], and the German and Australian assessments of suspected heart failure include it too [3,4]. The French nephrology textbook does not cite it [5].
On urine tests
- Urine protein:creatinine ratio (spot sample)
- Urine sediment
Sources (12)
- Moffatt CJ, Keeley V, Franks PJ, Rich A, Pinnington LL. Chronic oedema: a prevalent health care problem for UK health services. Int Wound J. 2017;14(5):772-81.
- Ely JW, Osheroff JA, Chambliss ML, Ebell MH. Approach to leg edema of unclear etiology. J Am Board Fam Med 2006;19(2):148-160.
- Bundesärztekammer, Kassenärztliche Bundesvereinigung, AWMF. Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz, Langfassung, version 4.0, 2023.
- Atherton JJ, Sindone A, De Pasquale CG, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Heart Lung Circ 2018;27(10):1123-1208.
- Syndromes oedémateux - Article complet. PDF
- Base de données publique des médicaments (ANSM/ministère de la Santé). Résumé des caractéristiques du produit : HYPERIUM 1 mg, comprimé (rilménidine), rubrique 4.8 (CIS 67541600).
- Base de données publique des médicaments (ANSM/ministère de la Santé). Résumé des caractéristiques du produit : AMLODIPINE ALMUS 5 mg, gélule, rubrique 4.8 (CIS 62042102).
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42(36):3599-3726.
- Haute Autorité de santé. Guide du parcours de soins : insuffisance cardiaque. Validé en février 2012, actualisé en juin 2014.
- National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management. NICE guideline NG106 (published 2018, amended 2025).
- Taylor CJ, Taylor KS, Jones NR, et al. Age-adjusted natriuretic peptide thresholds for a diagnosis of heart failure in the community: diagnostic accuracy study. ESC Heart Fail 2025;12(5):3552-3568 (rapporte les seuils proposés en 2023 par l'Association européenne d'insuffisance cardiaque).
- Patel H, Skok CJ, DeMarco A. Peripheral Edema: Evaluation and Management in Primary Care. Am Fam Physician 2022;106(5):557-564.